 Catalent
to nearly double U.S. production of Moderna's COVID-19 vaccine: WSJ
Send a link to a friend
[April 06, 2021]
(Reuters) - Contract manufacturer Catalent
Inc has signed an agreement that will nearly double the U.S. production
of Moderna Inc's COVID-19 vaccine, the Wall Street Journal reported on
Tuesday, citing people familiar with the matter.
|
|
 The agreement will increase the vaccine output at Catalent's
Bloomington, Indiana, plant this month to about 400 vials a minute,
WSJ reported.
Last month, Moderna said it expects to meet its promise of
delivering 100 million doses to the United States by the end of May
and another 100 million by the end of July, by delivering 40-50
million doses per month.
Catalent and Moderna did not immediately respond to Reuters requests
for comment.
[to top of second column] |
 The two companies signed an
agreement last June for Catalent to help produce
the Moderna vaccine. (https://bit.ly/3mmaObq)
(Reporting by Manas Mishra in Bengaluru; Editing
by Devika Syamnath)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
